Names and pronunciation
(bri-ga′-ti-nib) Alunbrig
PDF page 190
Drug reference
(bri-ga′-ti-nib) Alunbrig
PDF page 190
Func. class.: Antineoplastic
PDF page 190
USES: Advanced ALK-positive meta- static non–small-cell lung cancer who have progressed on or are intolerant to crizotinib
PDF page 190
DOSAGE AND ROUTES • Adult: PO 90 mg/day × 7 days; if toler- ated during the first 7 days, increase to 180 mg/day. Continue until disease pro- gression or unacceptable toxicity
PDF page 190
Available forms: Tablets 30, 90, 180 mg
PDF page 190
• Adult: PO 90 mg/day × 7 days; if toler- ated during the first 7 days, increase to 180 mg/day. Continue until disease pro- gression or unacceptable toxicity
PDF page 190